Vasoactive Intestinal Peptide Therapy for COPD, PAH, and Asthma
Author Information
Author(s): Wu Dongmei, Lee Dongwon, Sung Yong Kiel
Primary Institution: Mount Sinai Medical Center
Hypothesis
Can vasoactive intestinal peptide (VIP) serve as an effective treatment for pulmonary arterial hypertension (PAH), asthma, and chronic obstructive pulmonary disease (COPD)?
Conclusion
Vasoactive intestinal peptide (VIP) shows promise as a therapeutic agent for treating PAH, asthma, and COPD due to its various beneficial effects on the cardiopulmonary system.
Supporting Evidence
- VIP has potent vasodilatory and anti-inflammatory effects.
- VIP can improve blood circulation to the heart and lungs.
- VIP-based drugs may provide a novel therapeutic approach for PAH, asthma, and COPD.
Takeaway
Vasoactive intestinal peptide (VIP) is a special protein that can help treat breathing problems like asthma and COPD by relaxing blood vessels and reducing inflammation.
Methodology
This review summarizes existing research on the physiological significance and therapeutic potential of VIP in treating cardiopulmonary diseases.
Limitations
Clinical application of VIP has been limited due to its short plasma half-life and challenges in administration routes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website